We previously demonstrated that Busulfan-Thiotepa (BuThio) and ASCT effectively treated patients with locally relapsed medulloblastoma after surgery and conventional chemotherapy. We thus evaluated the administration of Bu-Thio in patients relapsing after conventional CNS irradiation. Patients were scheduled to receive Busulfan (600 mg/m 2 ) and Thiotepa (900 mg/m 2 ) and ASCT. Resection of residual tumour and additional irradiation were performed if necessary and feasible after Bu-Thio. Toxicity was compared to that observed in 35 patients treated without previous CNS irradiation. From 5/88 to 3/02, 15 patients were treated according to this strategy. Toxicity was significantly higher than that observed in unirradiated patients: thrombocytopenia o50 000/mm 3 lasting 56 days (13-732) (P ¼ 0.02) and 30 days (4-124), respectively, HVOD (10/15 and 12/35 patients, respectively) (P ¼ 0.06), neurological toxicity (8/15 vs 3/35 patients) (P ¼ 0.01). Tumour response was assessable in seven patients and consisted in two CR, three PR and two NR. Currently, two of 15 patients are alive with no evidence of disease. In conclusion, the toxicity of Bu-Thio was significantly more severe in previously irradiated patients. In spite of a high response rate, this strategy failed to improve the prognosis of previously irradiated patients with a relapse from a medulloblastoma. Bone Marrow Transplantation (2005) 36, 939-945.
Summary:
We previously demonstrated that Busulfan-Thiotepa (BuThio) and ASCT effectively treated patients with locally relapsed medulloblastoma after surgery and conventional chemotherapy. We thus evaluated the administration of Bu-Thio in patients relapsing after conventional CNS irradiation. Patients were scheduled to receive Busulfan (600 mg/m 2 ) and Thiotepa (900 mg/m 2 ) and ASCT. Resection of residual tumour and additional irradiation were performed if necessary and feasible after Bu-Thio. Toxicity was compared to that observed in 35 patients treated without previous CNS irradiation. From 5/88 to 3/02, 15 patients were treated according to this strategy. Toxicity was significantly higher than that observed in unirradiated patients: thrombocytopenia o50 000/mm 3 lasting 56 days (13-732) (P ¼ 0.02) and 30 days (4-124), respectively, HVOD (10/15 and 12/35 patients, respectively) (P ¼ 0.06), neurological toxicity (8/15 vs 3/35 patients) (P ¼ 0.01). Tumour response was assessable in seven patients and consisted in two CR, three PR and two NR. Currently, two of 15 patients are alive with no evidence of disease. In conclusion, the toxicity of Bu-Thio was significantly more severe in previously irradiated patients. In spite of a high response rate, this strategy failed to improve the prognosis of previously irradiated patients with a relapse from a medulloblastoma. Although central nervous system (CNS) tumours are the most common childhood malignant tumours after leukaemia, their management has progressed slowly during the past two decades.
Surgical excision of the primary tumour and craniospinal irradiation (54 Gy to the posterior fossa and 36 Gy to the craniospinal axis) continue to be the gold standard treatment for medulloblastoma. [1] [2] [3] [4] [5] [6] However, medulloblastoma has largely been demonstrated to be a chemosensitive tumour. [7] [8] [9] [10] [11] [12] Strategies using chemotherapy have been developed in young patients to delay or avoid radiotherapy because of the severe late side effects, especially neuro-psychological impairment particularly affecting children under 3 years of age. [11] [12] [13] [14] [15] [16] During the last 15 years, the benefits of high-dose multiagent chemotherapy with autologous stem cell transplantation (ASCT) have been evaluated. Some groups worldwide have used high-dose chemotherapy (HDCT) successfully to increase disease-free survival in medulloblastoma patients with recurrent disease. HDCT has been used predominantly in young children relapsing locally who were previously treated with chemotherapy alone. 17, 18 We previously demonstrated that a high-dose (HD) Busulfan-Thiotepa (Bu-Thio) conditioning regimen yielded a 75% response rate and could replace craniospinal irradiation in preventing metastatic disease in locally relapsing young patients, previously treated with conventional chemotherapy without irradiation. 17 However, the prognosis of patients relapsing after gold standard treatment combining surgery and craniospinal irradiation is very poor and new approaches are warranted. [19] [20] [21] [22] [23] [24] [25] [26] [27] We thus developed a strategy using HD Bu-Thio in patients in such a setting to evaluate the impact of this approach on their prognosis.
Patients relapsing after craniospinal irradiation were treated with HD Bu-Thio and stem cell transplantation and surgical excision of residual tumour if indicated. Additional irradiation was delivered when possible, taking into account previously administered irradiation doses.
We present here the toxicity and efficacy of HD Bu-Thio in a series of 15 patients and compare these results to those observed in unirradiated patients.
Patients and methods
Between May 1988 and March 2002, 15 children with relapsing medulloblastoma after conventional therapy admitted to the Paediatrics Department of the Institut Gustave Roussy, were treated with HD Bu-Thio. The median age at the time of the first diagnosis and HDCT was 89 months and 128 months (51-309), respectively. There were eight boys and seven girls. Patient characteristics are described in Table 1 .
At diagnosis, the disease was localised in 11 children and metastatic in four. All patients had undergone surgical excision of the primary tumour. Resection was complete in seven and subtotal in eight. Histological examination of the tumour confirmed the diagnosis of medulloblastoma in all patients. Conventional irradiation consisting in a craniospinal dose of 25-35 Gy and 50-55 Gy to the posterior fossa had been delivered to all but one patient (no. 4). Patient no. 4, who presented medulloblastoma as a second tumour, had previously received 18 Gy of craniospinal irradiation and subsequently 10 Gy of TBI for treatment of lymphoblastic leukaemia. All patients had received conventional chemotherapy for primary disease according to different protocols with a median of 4.5 drugs ( Table 1) .
The medulloblastoma relapse was local in seven children and metastatic in eight. At the time of HDCT, five patients were in a second CR, two patients were in a second VGPR, four patients were in a second PR and in one patient disease had stabilised for the second time.
Three patients entered the HDCT program without conventional treatment of a first relapse (two patients, nos. 1 and 6) and of a second relapse (one patient, no. 13). For details, see Table 2 . 
Eight in one ¼ carboplatin, vincristine, methylhydrazine, cyclophosphamide, cisplatinum, hydroxyurea, cytosine-arabinosine and prednisone. Hydration (3 l/m 2 /day) with 5% dextrose and an adequate concentration of electrolytes were maintained during the 7 days of chemotherapy.
Transplantation procedures. Hematopoietic stem cells from bone marrow or peripheral blood (PBSC) were collected and cryopreserved at the time of the relapse. Bone marrow or PBSC were infused 48 h after completion of chemotherapy (day 0).
Supportive care. Prophylactic therapy consisting of clonazepam (0.1 mg/kg/day), from À9 day to day 0 was administered to all patients against busulfan-related seizures. [28] [29] [30] All patients were isolated in laminar air-flow single rooms and were fitted with right atrial catheters on admission to the transplant unit. They received parenteral nutrition and broad-spectrum antibiotics, as previously described. 31 Platelet and packed red cell transfusions were transfused to maintain the platelet count 450 Â 10 9 /l and the haemoglobin level 470 g/l. All blood products were irradiated at a dose of 25 Gy before transfusion and CMVseronegative patients were transfused with sero-negative blood products.
Neutrophil recovery was defined as a blood neutrophil count above 0.5 Â 10 9 /l. Platelet recovery was defined as a blood platelet count above 50 Â 10 9 /l, independent of platelet transfusion.
Toxicity was evaluated according to the criteria defined by Bearman et al 32 and compared to that of 35 patients who received HDCT without previous irradiation during the same period.
Tumour response
Tumours were evaluated at the time of relapse with computed tomography and/or magnetic resonance imaging (MRI) and a lumbar puncture when possible (Table 2) . Tumour response was evaluated before HDCT and 4 to 6 weeks thereafter based on the product of two tumour diameters evaluated by neurological imaging, and after completion of the treatment.
Response criteria were determined according to published criteria and definitions for response and relapse in children with brain tumours (CR, VGPR, PR, OR, SD PD). 33 
Statistical methods
Differences between groups were evaluated by the w 2 test or Fisher's exact test for categorical variables and the Student's t-test for continuous variables (two-sided tests).
Results
The haematopoietic stem cell transplant consisted of bone marrow in seven cases, PBSC in seven cases and both in one. G-CSF was administered in 10/15 children for a mean duration of 10 days (7-38).
Toxicity
Toxicity is described in Table 3 and compared to that observed in 35 patients who received a HD Bu-Thio without previous irradiation during the same period.
Haematological toxicity
Myelosuppression was constant. The median duration of neutropenia and thrombocytopenia (o50 Â 10 9 /l) was 8.5 days (1-44) and 56 days (13-732), respectively. Patients were transfused with a median of three packed red cell transfusions (2-18) and a median of 22 platelet transfusions (7-80). Table 3 Comparison of HDCT toxicity according to irradiation before HDCT
Previously irradiated patients Unirradiated patients
Age at time of diagnosis (P ¼ 0. While previous irradiation had no impact on the duration of neutropenia, it was linked to significantly longer duration of thrombocytopenia (P ¼ 0.02) with significantly greater platelet transfusion requirements (P ¼ 0.006).
Infectious complications
Out of 15 patients, 13 experienced fever lasting a median duration of 13.5 days (range 1-56) and they received antibiotics for a median duration of 21 days (13-68). Bacterial infections were documented in two patients (Gram negative septicaemia (n ¼ 1) and interstitial pneumonitis (n ¼ 1)).
Similar data were observed in unirradiated patients. No patient died of an infectious complication during aplasia.
Delayed viral infections were observed in eight patients: zoster (n ¼ 3), varicella (n ¼ 1), herpes simplex infection (n ¼ 3) and BK virus infection (n ¼ 1). The incidence was not statistically different from that observed in unirradiated patients (9/35), P ¼ 0.26. All viral infections resolved under appropriate treatment.
Gastrointestinal toxicity
Gastrointestinal toxicity was common. Vomiting occurred in 5/15 patients, with no difference in incidence and severity as compared with unirradiated patients (P ¼ 0.54). Out of 15 patients, 13 experienced mucositis, which was moderate (grade 2) in one case and severe in 12. Its incidence and severity was not different from that of unirradiated patients. Nevertheless, the median duration of grade 2-3 mucositis was significantly longer in previously irradiated patients compared to the control group (P ¼ 0.02).
All children experienced grade 2-3 diarrhoea and there was no significant difference between the two groups (P ¼ 0.09). All patients experienced grade 2-3 anorexia.
Hepatotoxicity
In total, 11/15 children developed hepatic toxicity. A total of 10 presented hepatic venous-occlusive disease (HVOD) (one grade 1, six grade 2 and three grade 3). The incidence of grade X2 HVOD was higher in previously irradiated patients than in the control group, where 11/35 patients developed grade X2 HVOD (60 vs 31%) (P ¼ 0.06).
Haemorrhagic complications
Severe haemorrhagic complications were observed in four patients. Haemorrhagic cystitis requiring surgical removal of clots occurred in one case. An anterior nasal pack was inserted for severe epistaxis and associated with platelet transfusion in one patient who subsequently developed lung haemorrhage with pleural effusion and fatal respiratory distress syndrome. Meningeal haemorrhage with a subdural hematoma occurred in one patient. It improved after insertion of a subdural Omaya shunt. This patient subsequently developed severe gastrointestinal bleeding. Haemorrhagic enterocolitis was observed in one patient who had a favourable outcome.
Neurological toxicity
Intentional tremor was almost constant but resolved within a few weeks. Impairment of memory, hallucinations and fasciculations with altered EEG features were observed in one patient with a favourable outcome. Unusual somnolence was observed in four patients; it was associated with a pyramidal syndrome in one patient. One patient developed meningeal haemorrhage with coma that resolved.
Hepatic encephalopathy related to severe HVOD was documented in one patient; its outcome was favourable. Neurological impairment was associated with multiorgan failure that led to death in one patient. The incidence of neurological toxicity was significantly greater in previously irradiated patients compared to the control group (8/15 vs 3/35) (Po0.001).
Dermatological toxicity
Skin toxicity, consisting of erythro-melanodermia associated with skin excoriations, occurred in all patients.
Toxic deaths
Four patients died as a result of toxicity: multiorgan failure (n ¼ 3 cases) and gastrointestinal haemorrhagic complications with severe HVOD (n ¼ 1). One toxic death related to severe HVOD, associated with interstitial pneumonitis, occurred in the control group. The incidence of toxic deaths was significantly higher in previously irradiated patients (P ¼ 0.01).
Tumour response
Tumour response after HDCT was assessable in 7/10 patients with measurable disease, since three patients died of toxicity before evaluation. One patient in VGPR and one with progressive disease achieved a CR. A measurable response was observed in five patients: two CR, two VGPR and one PR. Disease remained stable in the other two patients (see Table 4 ). Post HDCT treatment is described in Table 4 . Surgical excision of residual tumour was performed in one patient. Radiotherapy was delivered after HDCT in four patients at a dose of 40-50 Gy to the site of a unique metastasis, as consolidation of a CR (n ¼ 3), for a persistent residue (n ¼ 1).
In March 2005, two patients were alive with no evidence of disease (158 months þ , 135 months þ post ASCT), one patient (patient no. 9) was lost to follow-up, four and eight patients died of toxicity and disease progression, respectively.
Discussion
In the literature, patients with low-risk or high-risk medulloblastoma, undergoing surgical resection of a posterior fossa tumour and craniospinal irradiation have a 5-year EFS of 70-80 and 50%, respectively. 9, [34] [35] [36] However, the prognosis of patients relapsing after such conventional treatment is very poor since median survival is 5 months with no long-term survivors after treatment combining surgery, conventional chemotherapy and radiation therapy. 26, 36, 37 We thus tried to improve the prognosis of these patients with HDCT followed by ASCT. This treatment intensification was combined with the standard approach, namely conventional chemotherapy, 2nd look surgery and complementary irradiation according to the clinical and radiological status and previous treatment each patient had received.
HDCT protocols have been developed for medulloblastoma relapsing after conventional treatments. Alkylating agents appear to be the most appropriate class of drugs for use in a high-dose setting, since they are the most active drugs in CNS tumours along with platinum derivates, and are characterised by a steep linear-log relationship. Thiotepa and its major metabolite, TEPA, attain cerebrospinal fluid (CSF) concentrations that are approximately equivalent to plasma concentrations. They display in vitro cytocidal activity against medulloblastoma with a steep dose-response curve. 37, 38 Busulfan crosses the blood-brain barrier with a CSF to plasma ratio of 1.39 when given at a dose of 600 mg/m 2 and its antitumour activity against medulloblastoma xenografts has been demonstrated in athymic nude mice. 39 The Bu-Thio combination efficiently induced a 75% response rate and cured patients with a local relapse without additional craniospinal irradiation. 17, 37 These encouraging results led us to administer this HDCT regimen as salvage treatment to older patients relapsing after conventional therapy. The toxicity of the HD BuThio combination is now well known and has been described not only in patients with medulloblastoma but also in patients with ependymoma, 40 and brain stem tumours. 41 In this series of previously irradiated patients, a significant increase in most toxicities was documented. Prolonged thrombocytopenia can be explained by damage to bone marrow stroma resulting from previous vertebral irradiation. [42] [43] [44] [45] The neurotoxicity of high doses of Busulfan and Thiotepa is well documented. 18, 29, 30, 46 The increased incidence of neurological complications can be explained by direct cumulated toxicity of previous irradiation and the neurotoxicity of these two compounds. Conversely, the increased visceral toxicity (digestive, hepatic and multiorgan) cannot be explained by a direct effect of previous irradiation since diffused irradiation does not pass beyond the anterior wall of vertebrae. The toxicity observed could be compared to that described after the administration of repeated courses of high-dose alkylating agents. 19, 22, [47] [48] [49] [50] These severe complications are no longer considered as organ related but rather linked to endothelial damage. 51, 52 Radiation therapy could induce endothelial changes that could lead to increased multiorgan sensitivity to alkylating agents.
Neurotoxicity was also severe when Bu-Thio was administered to patients with previously locally irradiated diffuse pontine gliomas. However visceral toxicity following localised radiotherapy was much lower than that observed after craniospinal irradiation. 41 Thus, the extent of previous irradiation should be considered as an important risk factor. In the present series, patients were significantly older than those in the control group and those treated for other tumours. 41 Thus, age at transplantation could also be a risk factor in children. However, age has no significant impact on toxicity when other high-dose alkylating agents are administered. The combination of Busulfan and Melphalan is used in young patients with high-risk neuroblastoma and in older patients with Ewing tumours without any significant difference in toxicity (E Benhamou, personal communication).
In this series, the toxic death rate was very high (26.6%) and unusual after a single course of HDCT. Even if promising results in terms of prophylaxis and treatment of HVOD have been shown with defibrotide administration, toxicity remains a major problem when administering highdose alkylating agents in such patients. [53] [54] [55] In spite of the low number of assessable patients, the response rate observed in these very heavily pretreated patients is high. However, long-term survival in the cohort was poor. The Table 4 Results of high-dose chemotherapy and ASCT high toxicity and the poor long-term survival indicate that this salvage strategy cannot be recommended for the treatment of patients relapsing after craniospinal irradiation. New therapeutic approaches will have to be evaluated for these patients.
Conclusion
In conclusion, HDCT with Bu-Thio followed by ASCT induced a high response rate in heavily pretreated relapsing medulloblastoma patients. However, given the low longterm control of the disease, visceral toxicity was considered too high. Previous craniospinal irradiation appears to be a major risk factor for the increased incidence and severity of toxicity.
